22 March 20213 minute read

Geoffrey Levitt joins DLA Piper's Litigation and Regulatory practice as co-chair of Life Sciences Policy and Regulatory group

DLA Piper announced today that Geoffrey Levitt has joined the firm’s Litigation and Regulatory practice as co-chair of the Life Sciences Policy and Regulatory group. He will be based in the Washington, DC office.

Levitt previously served as head of international affairs and policy for Viatris Inc., as senior vice president and chief counsel for Pfizer Inc.’s Upjohn division in China, and as chief regulatory counsel for Pfizer Inc. and Wyeth Pharmaceuticals. He will advise clients on a wide range of regulatory, policy and legislative issues impacting the healthcare and life sciences sectors.

“Geoff is widely considered to be one of the leading FDA regulatory lawyers in the pharmaceutical industry, and his addition solidifies our commitment to growing our healthcare and life sciences policy and regulatory capabilities,” said Loren Brown, DLA Piper's US vice chair. “His extensive in-house experience, coupled with his familiarity with the international markets in which our clients do business, will be highly beneficial to our clients.”

“Geoff brings a deep understanding of the multifaceted regulatory issues facing pharmaceutical companies, and his skillset and experience will enable us to meet the demand for knowledgeable counsel in these highly complex and constantly evolving areas,” added Matt Holian, global co-chair of DLA Piper’s Life Sciences sector.

Levitt received his J.D. from Harvard Law School, his M.A. in international affairs from Harvard University and his B.A. from Columbia University.